Medicosnext
Based on early data from the first-ever clinical trial in humans in the US, genetically editing a cancer patient’s immune cells using CRISPR/Cas9 technology and infusing them back into the patient seems to be safe and feasible. Three participants in the trial (two with multiple myeloma and one with sarcoma) …
Read More »First U.S. Trial of CRISPR- edited Immune Cells for Cancer Patients to Gauge Safety
